Neurometrix Inc (NASDAQ:NURO) has coverage initiated with a Buy rating

ME Staff
-
0

Analyst Ratings For Neurometrix Inc (NASDAQ:NURO)

Today, HC Wainwright initiated coverage on Neurometrix Inc (NASDAQ:NURO) with a Buy.

There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Neurometrix Inc (NASDAQ:NURO) is Buy with a consensus target price of N/A per share, a potential N/A.

Some recent analyst ratings include

  • 12/26/2018-Neurometrix Inc (NASDAQ:NURO) has coverage initiated with a Buy rating
  • On 10/29/2018 Shai Gozani, CEO, sold 3,760 with an average share price of $1.18 per share and the total transaction amounting to $4,436.80.
  • On 3/1/2018 Thomas T Higgins, Insider, bought 1,000 with an average share price of $1.33 per share and the total transaction amounting to $1,330.00.
  • On 2/23/2018 Shai Gozani, CEO, bought 1,500 with an average share price of $1.54 per share and the total transaction amounting to $2,310.00.
  • On 2/20/2018 Shai Gozani, CEO, bought 1,000 with an average share price of $1.36 per share and the total transaction amounting to $1,360.00.
  • On 2/20/2018 Thomas T Higgins, Insider, bought 1,500 with an average share price of $1.36 per share and the total transaction amounting to $2,040.00.
  • On 2/12/2018 Francis X Mcgillin, SVP, bought 3,849 with an average share price of $1.30 per share and the total transaction amounting to $5,003.70.
  • On 2/12/2018 Thomas T Higgins, Insider, bought 1,500 with an average share price of $1.34 per share and the total transaction amounting to $2,010.00.

About Neurometrix Inc (NASDAQ:NURO)
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Asia, the Middle East, Mexico, and internationally. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

Recent Trading Activity for Neurometrix Inc (NASDAQ:NURO)
Shares of Neurometrix Inc closed the previous trading session at 0.68 −0.021 2.96% with 88400 shares trading hands.